Literature DB >> 27553929

Prospective 1-year follow-up pilot study of CT-guided microwave ablation in the treatment of bone and soft-tissue malignant tumours.

Sébastien Aubry1,2, Jonathan Dubut3, Jean-Philippe Nueffer3, Loic Chaigneau4, Chrystelle Vidal5, Bruno Kastler3,6.   

Abstract

PURPOSE: The aims of this work were to assess the feasibility, efficacy, short-term outcome and safety of microwave ablation (MWA) in the treatment of malignant musculoskeletal tumours.
MATERIALS AND METHODS: Sixteen bone and soft-tissue malignant tumours were prospectively included and were treated by CT-guided MWA. The percentage and size of necrosis of the lesions were measured by contrast-enhanced MRI before the procedure and after 1, 3, 6 and 12 months. mRECIST criteria were used to assess tumour response. Procedural success was defined as ≥80 % necrosis. Patient pain (as assessed using a numeric visual scale (NVS)) and side effects were noted.
RESULTS: Six osteolytic metastases, five osteoblastic metastases and five soft tissue sarcomas were treated. At 1 month, 40 % were treated completely, the percentage of necrosis was 85 ± 30.4 %, and the success rate was 80 %. At 3, 6 and 12 months the success rate was 80 %, 76.9 % and 63.6 %, respectively. At 12 months, four lesions (36.3 %) still had no recurrence. Mean NVS during the procedure was 3.5 ± 2.8. One patient had transitory sciatica without neurological deficit that was treated medically.
CONCLUSION: CT-guided MWA of bone and soft-tissue malignant tumours is efficient, well tolerated and has good short-term anti-cancer effects. KEY POINTS: • CT-guided MWA is efficient in treating musculoskeletal malignant tumours. • This prospective pilot study showed MWA induces high percentages of tumour necrosis. • MWA has good short-term anti-cancer effects. • MWA has healing potential when lesions can be completely necrosed. • CT-guided MWA under equimolar mixture of oxygen-nitrous oxide inhalation is well tolerated.

Entities:  

Keywords:  Bone metastasis; CT-guided; Microwave ablation; Soft tissue tumour; Thermoablative therapy

Mesh:

Year:  2016        PMID: 27553929     DOI: 10.1007/s00330-016-4528-7

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  7 in total

Review 1.  Thermal Ablation of Bone Metastases.

Authors:  Michael R Moynagh; A Nicholas Kurup; Matthew R Callstrom
Journal:  Semin Intervent Radiol       Date:  2018-11-05       Impact factor: 1.513

Review 2.  Cytoreduction for colorectal metastases: liver, lung, peritoneum, lymph nodes, bone, brain. When does it palliate, prolong survival, and potentially cure?

Authors:  Camille L Stewart; Susanne Warner; Kaori Ito; Mustafa Raoof; Geena X Wu; Jonathan Kessler; Jae Y Kim; Yuman Fong
Journal:  Curr Probl Surg       Date:  2018-10-04       Impact factor: 1.909

Review 3.  Image-Guided Thermal Ablative Therapies in the Treatment of Sarcoma.

Authors:  Scott M Thompson; John J Schmitz; Grant D Schmit; Matthew R Callstrom; Anil Nicholas Kurup
Journal:  Curr Treat Options Oncol       Date:  2017-04

Review 4.  Minimally Invasive Interventional Procedures for Metastatic Bone Disease: A Comprehensive Review.

Authors:  Nicolas Papalexis; Anna Parmeggiani; Giuliano Peta; Paolo Spinnato; Marco Miceli; Giancarlo Facchini
Journal:  Curr Oncol       Date:  2022-06-07       Impact factor: 3.109

5.  The effects of combined microwave ablation and open surgery for the treatment of lung cancer-derived thoracolumbar metastases.

Authors:  Guoqing Zhong; Longhui Zeng; Yue He; Xiaolong Zeng; Wenhan Huang; Tao Yang; Xiao Chu; Jin Xiao; Dong Yin; Yunbing Chang; Shi Cheng; Yu Zhang
Journal:  Orthop Surg       Date:  2022-05-23       Impact factor: 2.279

Review 6.  Surgical Approach to Bone Metastases.

Authors:  Geoffrey W Siegel; J Sybil Biermann; Anda-Alexandra Calinescu; Daniel E Spratt; Nicholas J Szerlip
Journal:  Curr Osteoporos Rep       Date:  2018-08       Impact factor: 5.096

Review 7.  Interventional Radiology in the Management of Metastases and Bone Tumors.

Authors:  Ferruccio Sgalambro; Luigi Zugaro; Federico Bruno; Pierpaolo Palumbo; Nicola Salducca; Carmine Zoccali; Antonio Barile; Carlo Masciocchi; Francesco Arrigoni
Journal:  J Clin Med       Date:  2022-06-07       Impact factor: 4.964

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.